CD7, a surface protein found on AML cells, actively drives chemoresistance rather than just signaling a poor prognosis, reframing its role from marker to driver.

Overall, the research redefines CD7 as an active driver of chemoresistance in AML, outlining actionable components of its signaling network and interactions with the microenvironment.

Caveats include the need for careful NF-κB targeting due to its role in immune defense, reliance on cell line models, and the need for prospective validation and companion diagnostics to identify patients who would benefit.

NF-κB activation in CD7-positive cells upregulates P-glycoprotein 1 and maintains XIAP, enabling drug efflux and resistance to cell death.

RNA sequencing and pathway analyses show CD7-positive cells are dominated by NF-κB target genes and inflammatory signaling, reinforcing the link to chemoresistance.

Functional experiments reveal CD7 enhances proliferation, speeds up the cell cycle, and inhibits differentiation, increasing leukemic fitness.

Clinically, this supports extending CD7-targeted therapies (antibody-drug conjugates, CAR-T) to CD7-positive AML and suggests inhibiting NF-κB, P-glycoprotein, or XIAP could resensitize tumors to cytarabine and daunorubicin.

CD7-positive AML cells survive cytarabine and daunorubicin at doses that kill CD7-negative cells, demonstrating a robust resistance mechanism centered on NF-κB signaling.

The inflammatory bone marrow environment, via IL-1β and TNF-α, amplifies NF-κB activation in a CD7-dependent manner, implying a feedback loop where chemotherapy-induced inflammation strengthens resistance.

The study combined single-cell proteomics (CyTOF) with public transcriptomic data to show CD7 is widely present across AML subtypes and enriched in early-stage myeloid cells, suggesting a stem-like, aggressive leukemia population.